Clinical Trial Update: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel with bevacizumab or ipilimumab as first-line therapy in patients with unresectable stage IV melanoma (cutaneous, mucosal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Mucosal Melanoma
• Unresectable Melanoma
• Uveal Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Nab-paclitaxel (paclitaxel protein-bound)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Metastatic Melanoma, Mucosal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-01-02